Research programme: LOX inhibitors - Pharmaxis

Drug Profile

Research programme: LOX inhibitors - Pharmaxis

Alternative Names: LOX inhibitors - Pharmaxis; LOXL2 inhibitors - Pharmaxis; PXS 5382A; PXS-5338K

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmaxis
  • Developer Pharmaxis; Synairgen
  • Class Antifibrotics; Antineoplastics; Pyrans; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors; Protein-lysine 6-oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Hepatic fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis

Most Recent Events

  • 12 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in Australia (PO), before October 2017 (ACTRN12617001444370)
  • 12 Oct 2017 Pharmaxis plans a phase I trial for Non-alcoholic steatohepatitis (In volunteers) in Australia in October 2017 (ACTRN12617001444370)
  • 06 Sep 2017 Synairgen in collaboration with Pharmaxis plans a phase I trial of a PXS-5382A for Pulmonary fibrosis in Q4 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top